Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain training and extra support may cut opioid misuse in cancer patients

NCT ID NCT05077072

Symptom relief Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two pain management approaches—neurofeedback (brain wave training) and a supportive care team—against standard care in 28 head and neck cancer patients at risk of misusing opioids. The goal is to see if these methods can lower pain and reduce the need for strong painkillers. Participants must be 18 or older, scheduled for radiation, and have a history of opioid misuse risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

28 people

The number who actually took part.

Started

Oct 2021

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of HNC, with patient scheduled to receive radiation therapy, with or without evidence of active disease * Willingness to be seen in the outpatient supportive care center (SCC) * History of use of non-medical opioid use (Screener and Opioid Assessment for Patients with Pain \[SOAPP\] \>= 7+ and/or Cut Down, Annoyed, Guilty, and Eye opener questionnaire \[CAGE\] \>= 2+) * Physician-estimated prognosis of at least 12 months * Age 18 or older * Able to complete study assessments * Willing to sign written informed consent * Both human papillomavirus (HPV) and non-HPV patients will be included * Patients currently receiving opioids for at least 1 week * Able to read, write and speak English Exclusion Criteria: * Individual with clinically evident impaired cognition by Memorial Delirium Assessment Scale (MDAS) score of \>= 13 * Employees of MD Anderson Cancer Center

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer head and neck carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck carcinoma

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.